NYSE: AORTArtivion Inc Stock
$24.43+0.23 (+0.95%)
Updated Mar 21, 2025
AORT Price
$24.43
Fair Value Price
N/A
Market Cap
$1.03B
52 Week Low
$19.36
52 Week High
$32.33
P/E
-76.34x
P/B
3.72x
P/S
3.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$388.54M
Earnings
-$13.36M
Gross Margin
64%
Operating Margin
6.89%
Profit Margin
-3.4%
Debt to Equity
1.86
Operating Cash Flow
$22M
Beta
1.11
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AORT Overview
Artivion, Inc. distributes cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. The human tissues distributed by Artivion include the CryoValve SG pulmonary human heart valve and the CryoPatch SG pulmonary cardiac patch tissue, both processed using Artivion's proprietary SynerGraft technology. Artivion's medical devices consist of surgical adhesives, sealants, and hemostats, as well as On-X Heart Valves, and aortic stent-grafts. Artivion, Inc. was incorporated in 1984 and is based in Kennesaw, GA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AORT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AORT
Ranked#73 of 109
Ranked#73 of 109
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.65 | A | |
| $24.73 | A | |
| $13.29 | A |
Be the first to know about important AORT news, forecast changes, insider trades & much more!
AORT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AORT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AORT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AORT is good value based on its book value relative to its share price (3.72x), compared to the US Medical Devices industry average (3.95x)
P/B vs Industry Valuation
AORT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more AORT due diligence checks available for Premium users.
Valuation
AORT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-76.34x
Industry
42.4x
Market
31.55x
AORT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.72x
Industry
3.95x
AORT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AORT's financial health
Profit margin
Revenue
$97.3M
Net Income
-$16.5M
Profit Margin
-16.9%
AORT's Earnings (EBIT) of $26.76M... subscribe to Premium to read more.
Interest Coverage Financials
AORT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$789.1M
Liabilities
$512.9M
Debt to equity
1.86
AORT's short-term assets ($290.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AORT's long-term liabilities ($446.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AORT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AORT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$10.1M
Investing
-$11.4M
Financing
$174.0k
AORT's operating cash flow ($22.24M)... subscribe to Premium to read more.
Debt Coverage Financials
AORT vs Medical Device Stocks
Artivion Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.